Montana Receives $1.2M in Settlement with GSK
The State of Montana is set to receive $1.2 million from a multi-state settlement with pharmaceutical company GlaxoSmithKline (GSK).
In addition to Montana, 43 other states and the District of Columbia have reached a $105 million settlement with GSK over illegal labeling and marketing of three of the companies drugs: Anti-depressants Paxil and Wellbutrin, and the asthma medication Advair.
About the GSK Settlements
According to KRTV, a nine-page complaint filed June 5th, 2014 in District Court in Helena says that between 1999 and 2003 GSK “deceptively promoted Paxil as safe and effective for children and adolescents, despite lack of FDA approval and three GSK clinical trials…and that Paxil may be associated with an increased risk of suicide in such patient population.”
The complaint also stated that GSK also never submitted substantial evidence of safety and efficacy for Wellbutrin, and Advair possessed false representations to promote the drug in terms of labeling.
Additionally, the filing indicates that GSK provided incentives to its sales representatives to make false statements about the Advair.
GSK denied any wrongdoing or liability; however, the company did agree to alter its marketing and the promotion of its drugs.
Montana’s $1.2$ million portion of the settlement will go to consumer protection service.
Side Effects of Advair, Paxil, and Welbutrin
RECENT MEDICAL MALPRACTICE RESULT
$10.9 MillionExpenses: $175,000.00 | Attorneys Fees: $3,200,000.00 | Net to Client: $4,029,762.00 (Purchase of a Lifetime Annuity)
RECENT VEHICLE RECALL RESULT
$30.2 MillionExpenses: $39,576.15 | Attorneys Fees: $10,060,980.00 | Net to Client: $20,121,960.57